- If you are wondering whether Danaher is starting to look attractively priced or still has more room to fall, its recent share performance and valuation checklist provide a useful starting point.
- The stock last closed at US$198.80, with returns of a 3.5% decline over 7 days, 8.2% decline over 30 days, 13.7% decline year to date, 2.5% decline over 1 year, 5.3% decline over 3 years, and a 5.6% gain over 5 years.
- Recent coverage has focused on Danaher as a large US healthcare and life sciences group that sits at the crossroads of diagnostics, scientific research tools, and biopharma services. This positioning can influence how investors think about its long-term role in healthcare. Commentary has also highlighted how broader sentiment…
Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?
Share this article
More News
Analysts reset Broadcom stock price target
May 21, 2026
Lumentum Stock Analysis: Buy or Sell?
May 21, 2026